Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin)

SAN DIEGO--(BUSINESS WIRE)--Jun. 29, 2018-- Acadia Pharmaceuticals Inc. today announced FDA approval of a new capsule dose formulation and a new tablet strength of Nuplazid (pimavanserin) to help in the treatment of patients living with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news